JP2025513344A - 眼科用局所クリーム組成物 - Google Patents

眼科用局所クリーム組成物 Download PDF

Info

Publication number
JP2025513344A
JP2025513344A JP2024561808A JP2024561808A JP2025513344A JP 2025513344 A JP2025513344 A JP 2025513344A JP 2024561808 A JP2024561808 A JP 2024561808A JP 2024561808 A JP2024561808 A JP 2024561808A JP 2025513344 A JP2025513344 A JP 2025513344A
Authority
JP
Japan
Prior art keywords
treatment composition
ophthalmic
therapeutic treatment
api
ophthalmic therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024561808A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025513344A5 (cg-RX-API-DMAC7.html
Inventor
シーア,ジェームズ・ジェーン-グオ
リウ,シャオジュン・マイケル
セーケイ,ガブリエラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaukos Corp
Original Assignee
Glaukos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaukos Corp filed Critical Glaukos Corp
Publication of JP2025513344A publication Critical patent/JP2025513344A/ja
Publication of JP2025513344A5 publication Critical patent/JP2025513344A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024561808A 2022-04-21 2023-04-19 眼科用局所クリーム組成物 Pending JP2025513344A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263363356P 2022-04-21 2022-04-21
US63/363,356 2022-04-21
PCT/US2023/065956 WO2023205695A1 (en) 2022-04-21 2023-04-19 Ophthalmic topical cream compositions

Publications (2)

Publication Number Publication Date
JP2025513344A true JP2025513344A (ja) 2025-04-24
JP2025513344A5 JP2025513344A5 (cg-RX-API-DMAC7.html) 2026-03-24

Family

ID=86558713

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024561808A Pending JP2025513344A (ja) 2022-04-21 2023-04-19 眼科用局所クリーム組成物

Country Status (7)

Country Link
US (2) US12414938B2 (cg-RX-API-DMAC7.html)
EP (1) EP4511001A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025513344A (cg-RX-API-DMAC7.html)
CN (1) CN119584954A (cg-RX-API-DMAC7.html)
AU (1) AU2023257375A1 (cg-RX-API-DMAC7.html)
CA (1) CA3249922A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023205695A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026060434A1 (en) * 2024-09-16 2026-03-19 Iview Therapeutics, Inc. Novel eyelid delivery of ophthalmic composition containing muscarinic receptor modulators for prevention and treatment of ocular disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2752008T3 (es) 2009-10-30 2020-04-02 Intratus Inc Métodos y composiciones para la liberación sostenida de fármacos
US20120195969A1 (en) 2010-09-29 2012-08-02 Aidan Research And Consulting, Llc Treatment of acne by conditioned media
DK2645993T3 (en) 2010-12-03 2017-02-13 Allergan Inc Pharmaceutical cream compositions comprising oxymetazoline
BR112015031885A2 (pt) 2013-06-18 2017-07-25 Lubrizol Advanced Mat Inc dispersões estáveis coloidalmente com base em galactomananas modificadas
CN113559105B (zh) 2014-01-29 2026-06-23 维奥姆治疗有限公司 抗性痤疮的治疗
US20170266289A1 (en) * 2014-08-27 2017-09-21 Abbvie Inc. Topical formulation
US20170087199A1 (en) 2016-02-10 2017-03-30 Senomyx, Inc. Compositions for delivering a cooling sensation
CA3032695C (en) * 2016-08-19 2021-11-23 Akrivista, LLC Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye
US11160780B2 (en) * 2016-09-30 2021-11-02 Aurobindo Pharma Ltd. Pharmaceutical composition of ivermectin and process for preparation thereof
JP6946575B2 (ja) 2018-04-24 2021-10-06 アラーガン、インコーポレイテッドAllergan,Incorporated 眼の状態の治療のためのピロカルピン塩酸塩の使用
DK3870170T3 (da) * 2018-10-26 2026-05-26 Opus Genetics Inc Behandling af presbyopi og mydriasis med fentolamin
WO2020141482A1 (en) * 2019-01-04 2020-07-09 Glenmark Specialty S.A. Pharmaceutical compositions comprising mupirocin
NZ781774A (en) * 2019-03-08 2023-03-31 Taro Pharma Ind Stable topical compositions of fenoldopam
US20220071924A1 (en) * 2019-03-19 2022-03-10 Sol-Gel Technologies Ltd. Treatment of ocular diseases with ophthalmic tapinarof compositions
WO2024026365A1 (en) 2022-07-26 2024-02-01 Glaukos Corporation Ophthalmic topical cream formulations and uses thereof

Also Published As

Publication number Publication date
WO2023205695A1 (en) 2023-10-26
US20230381145A1 (en) 2023-11-30
US20250387372A1 (en) 2025-12-25
EP4511001A1 (en) 2025-02-26
US12414938B2 (en) 2025-09-16
AU2023257375A1 (en) 2024-11-07
CA3249922A1 (en) 2023-10-26
CN119584954A (zh) 2025-03-07

Similar Documents

Publication Publication Date Title
KR101809713B1 (ko) 방부제 없는 프로스타글란딘계 비점성 용액의 고분자 전달 시스템
KR101792200B1 (ko) 열감응성 겔 마취제 조성물
WO2023225551A1 (en) Novel applications of zwitterions in ophthalmic topical cream compositions and preparations
TW201105363A (en) Eye drop for macular edema treatment
JP2022537139A (ja) 抗老眼効果を増強するためのカルバコール-ブリモニジン製剤
US20250387372A1 (en) Ophthalmic topical cream compositions and methods
EP0517160B1 (en) Extended-release ophthalmic preparations
TW201815397A (zh) 眼科用劑、眼科用藥、以及(a)羥丙基甲基纖維素及(b)維生素e類的用途
TW202011947A (zh) 淚液層穩定劑和瞼脂分泌促進劑、以及眼科用組成物
US20130023575A1 (en) Compositions and methods for the treatment of ocular surface allergies
JP2025513344A5 (cg-RX-API-DMAC7.html)
JP7331149B2 (ja) 直腸および局所投与のためのゲル
TW202033186A (zh) 眼科用組成物
JP7192489B2 (ja) 眼科用組成物
JP2022537460A (ja) キシログルカン及びアルコールを含む、活性成分の制御放出のためのゲル形態の医薬組成物
JPS63502270A (ja) 散瞳作用を有する眼科用医薬組成物
JP5957517B2 (ja) 結膜弛緩症治療用の点眼薬
US20260007595A1 (en) Eye drop formulations containing chondroitin sulfate for relieving ocular pain or discomfort
KR20070061578A (ko) 눈물 및 침 건조증 치료용 의약 조성물
WO2021180913A1 (en) New use and method of treatment
HK1178446B (en) Polymeric delivery system for a nonviscous prostaglandin-based solution without preservatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260313